Home Back

Diffuse Large B-Cell Lymphoma Prognosis (R-IPI)

Age
Performance Status
Lactate Dehydrogenase
Extranodal Involvement
Stage
Score
Prognosis according to the R-IPI (Revised International Prognostic Index)
Predicted 4-year Progression-Free Survival Rate
Estimated Overall Survival

Result Interpretation

Before the advent of anthracycline-based immunochemotherapy combined with rituximab, the original International Prognostic Index (IPI) was established and validated. Clinical trials have confirmed that rituximab can provide survival benefits for patients with diffuse large B-cell lymphoma.

The Revised International Prognostic Index (R-IPI) was established to predict outcomes for those receiving chemotherapy combined with rituximab. This score can classify patients into three groups (very good prognosis, good prognosis, poor prognosis), with survival rates for all three groups being >50% in the era of new therapies.

References

Research Paper The original IPI was developed by Shipp et al. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987-994. Research Paper The newer prognostic index was revised/developed by Sehn et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861.